Key points from article :
Camena Bioscience has closed a $10 million Series A financing round to advance its DNA synthesis technology.
Funding will be used to expand operations and further develop Camena’s DNA synthesis platform, known as gSynth.
Use of synthetic genes is crucial for researchers in understanding disease mechanisms and facilitating the drug discovery process.
Traditional DNA synthesis methods developed in the 1980s have limitations in terms of cost, time, and accuracy.
To overcome these challenges, Camena deploys an enzymatic approach to precisely produce synthetic DNA.
“gSynth platform is revolutionising the DNA synthesis market by unlocking access to genes and accelerating discovery pipelines,” - Steve Harvey, CEO of Camena.
Camena's approach simplifies complex supply chains and minimizes environmental impact.
Achieves 90% accuracy in DNA synthesis for sequences over 300 base pairs, while traditional technology only reaches ~30% accuracy.
“Our goal is to enable our customers to 'write' DNA with the same confidence and ease,” added Harvey.
